Jin Medical International Ltd (ZJYL) FinancialsZJYLFinancialJin Medical International Ltd

Jin Medical International Ltd (ZJYL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Wheelchair, accounting for 72.9% of total sales, equivalent to $7.69M. Another important revenue stream is Wheelchair components and others. Understanding this composition is critical for investors evaluating how ZJYL navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Jin Medical International Ltd maintains a gross margin of 24.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.60%, while the net margin is 0.09%. These profitability ratios, combined with a Return on Equity (ROE) of 6.62%, provide a clear picture of how effectively ZJYL converts its operational activities into shareholder value.

In the context of the broader market, ZJYL competes directly with industry leaders such as AIRS and PDEX. With a market capitalization of $18.39M, it holds a significant position in the sector. When comparing efficiency, ZJYL's gross margin of 24.31% stands against AIRS's 54.39% and PDEX's 30.74%. Such benchmarking helps identify whether Jin Medical International Ltd is trading at a premium or discount relative to its financial performance.

The company has a high P/E ratio of 168.14 and a price-to-sales ratio of 8.86, suggesting overvaluation compared to its earnings and sales.